NIH grants $2.3M to evaluate the impact of ViTrack® on maternal and child health during pregnancy
NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Dynocardia, developer of ViTrack, the first-of-its-kind non-invasive, wearable blood pressure (BP) and heart monitor, and NYC Health + Hospitals, the nation's largest safety net health system, are partnering on a study of hypertensive diseases of pregnancy (HDP). The study will include at least 150 women who are pregnant or have recently given birth. The perinatal study addresses a long-standing unmet need for accurate and continuous BP for reliable diagnosis of HDP and for prediction and early detection of preeclampsia. The research is being funded by a $2.3M grant from the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI).
- The research is being funded by a $2.3M grant from the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI).
- HDP, a constellation of high BP disorders that may occur during pregnancy, affects both the mother and the child and is a leading cause of pregnancy-related complications and death globally.
- While the risks posed by HDP have doubled over the past decade in the United States, the effects on the maternal population are not evenly distributed.
- Moreover, pregnant women are even more vulnerable to these errors due to hemodynamic and vascular changes that occur during pregnancy.